BHCM
CHRS icon

Brevan Howard Capital Management’s Coherus Oncology CHRS Stock Holding History

Brevan Howard Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-46,021
Closed -$79.6K – 1172
2024
Q2 		$79.6K Buy
46,021
+32,799
+248% +$66K ﹤0.01% 983
2024
Q1 		$31.6K Sell
13,222
-60,340
-82% -$148K ﹤0.01% 952
2023
Q4 		$245K Buy
73,562
+62,110
+542% +$166K ﹤0.01% 804
2023
Q3 		$42.8K Buy
+11,452
New +$52.9K ﹤0.01% 368

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brevan Howard Capital Management's CHRS Position: Q3 2024 in Review

Brevan Howard Capital Management sold out of Coherus Oncology (CHRS) in Q3 2024, closing a stake of 46,021 shares — an estimated $79.6K sold.

Brevan Howard Capital Management first reported a position in CHRS in Q3 2023 and held it in 4 quarters. The position peaked at $245K in Q4 2023. 128 funds tracked by Wall St. Rank hold CHRS as of Q3 2024.

  • Brevan Howard Capital Management reported no remaining Coherus Oncology position as of Q3 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 46,021 Coherus Oncology shares in Q3 2024, an estimated $79.6K.
  • Brevan Howard Capital Management first reported a position in Coherus Oncology in Q3 2023 and held it in 4 quarters.
  • Brevan Howard Capital Management's Coherus Oncology position peaked at $245K in Q4 2023.
  • 128 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2024.

Based on Brevan Howard Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.